BridgeMD
Is there an effect of local vaginal estrogen treatment on the hemostatic parameters in postmenopausal women?
EU CTIS ID: 2024-519539-41-00
What this study is testing
The aim of this study is to assess the hemostatic balance in postmenopausal women receiving local vaginal estrogen treatment by applying specific assays for coagulation and fibrinolysis.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Postmenopausal women aged ≥ 50 without previous VTE, having vulva vaginal atrophy symptoms and indication for standard treatment with vaginal estrogen 10 µg at least three times a week.
- Postmenopausal women aged ≥ 50 with previous VTE, having vulva vaginal atrophy symptoms and indication for standard treatment with vaginal estrogen 10 µg at least three times a week.
You likely can't join if
- Unable to give written informed consent due to language difficulties
- Currently cancer treatment
- Currently in treatment with blood thinning medication (except plateletinhibitor)
- Currently in treatment with local or systematic estrogen
- Systemic inflammatory disease, liver disease or kidney disease
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.